KAPA Key Statistics, Chart & Performance
The current stock price of KAPA is 0.752 USD. In the past month the price increased by 3.3%. In the past year, price decreased by -55.24%.
KAPA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.21 | 404.36B | ||
| AMGN | AMGEN INC | 15.16 | 178.50B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.45 | 116.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 781.76 | 52.67B | ||
| INSM | INSMED INC | N/A | 37.70B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 10.44 | 25.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.34 | 21.98B | ||
| INCY | INCYTE CORP | 15.72 | 19.81B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About KAPA
Company Profile
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The company is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Company Info
KAIROS PHARMA LTD
2355 Westwood Blvd. #139
Los Angeles CALIFORNIA US
Employees: 1
Phone: 18184045541
KAIROS PHARMA LTD / KAPA FAQ
What does KAIROS PHARMA LTD do?
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The company is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
What is the current price of KAPA stock?
The current stock price of KAPA is 0.752 USD. The price decreased by -6.58% in the last trading session.
Does KAIROS PHARMA LTD pay dividends?
KAPA does not pay a dividend.
What is the ChartMill rating of KAIROS PHARMA LTD stock?
KAPA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for KAIROS PHARMA LTD?
KAIROS PHARMA LTD (KAPA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for KAIROS PHARMA LTD?
KAIROS PHARMA LTD (KAPA) has a market capitalization of 15.66M USD. This makes KAPA a Nano Cap stock.
KAPA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KAPA. When comparing the yearly performance of all stocks, KAPA is a bad performer in the overall market: 92.9% of all stocks are doing better.
KAPA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KAPA. KAPA has a great financial health rating, but its profitability evaluates not so good.
KAPA Financial Highlights
Over the last trailing twelve months KAPA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -33.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.76% | ||
| ROE | -66.05% | ||
| Debt/Equity | 0 |
KAPA Forecast & Estimates
9 analysts have analysed KAPA and the average price target is 8.5 USD. This implies a price increase of 1030.32% is expected in the next year compared to the current price of 0.752.